Loading…
Loading…
Announcements from Anixa Biosciences, published the moment they cross the wire. Get them by email.
2025
Aug 25, 2025
9:13 AM EDT
Management will participate in the H.C. Wainwright 27 th Annual Global Investment Conference being held September 8 th – 10 th , 2025 at the Lotte New York Palace Hotel in New York City .
Aug 20, 2025
8:37 AM EDT
The Chinese National Intellectual Property Administration (CNIPA) has issued a Notice of Allowance for a new patent related to its breast cancer vaccine technology.
Aug 18, 2025
9:00 AM EDT
The second patient in the fourth dose cohort has been treated in the ongoing Phase 1 clinical trial evaluating the Company's novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center ("Moffitt").
Aug 12, 2025
8:05 AM EDT
The United States Patent and Trademark Office (USPTO) has issued U.S. Patent Number 12,384,826 covering its chimeric antigen receptor-T cell (CAR-T) technology. This new patent extends protection of Anixa's CAR-T technology to 2045.
Aug 08, 2025
9:15 AM EDT
Dr. Robert Wenham , Chair of the Gynecologic Oncology Program at Moffitt Cancer Center and principal investigator for the Company's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial, will be presenting at the 13 th Annual Ovarcoming Cancer Conference, being held September 18 – 19, 2025, virtually and…
Aug 04, 2025
8:45 AM EDT
That, in collaboration with Cleveland Clinic, it has initiated the transfer of the Investigational New Drug (IND) application that supported the Phase 1 clinical trial of its breast cancer vaccine.
Jul 30, 2025
8:15 AM EDT
The Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a new patent related to its breast cancer vaccine technology. This patent, exclusively licensed from Cleveland Clinic, will provide composition-of-matter protection for the Company's novel immunogenic approach to breast cancer…
Jul 24, 2025
8:00 AM EDT
The United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,370,244 on July 29, 2025 , covering key aspects of the Company's breast cancer vaccine technology.
Jul 09, 2025
8:00 AM EDT
The United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,357,593 on July 15, 2025 covering key aspects of its ovarian cancer vaccine technology.
Jun 23, 2025
8:00 AM EDT
It has dosed its first patient in the fourth dosage cohort in the ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer.
Jun 20, 2025
7:30 AM EDT
It will host an investor webcast presentation on June 26, 2025 at 2:00 PM EDT .
Jun 10, 2025
7:00 AM EDT
Its CEO, Dr. Amit Kumar , was interviewed by the New York Post to discuss Anixa's breast cancer vaccine, and the breast cancer vaccine was featured on Fox News' "Fox & Friends." Both the New York Post and Fox News highlighted the potential of Anixa's vaccine to change the paradigm for breast cancer treatment and…
Jun 09, 2025
8:00 AM EDT
Dr. Robert Wenham , Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, and the principal investigator of the Phase 1 clinical trial of Anixa's ovarian cancer CAR-T immunotherapy, will present an e-poster at the European Society for Medical Oncology ("ESMO") Gynaecological Cancers Congress 2025, to be…
Jun 03, 2025
7:25 AM EDT
Its CEO, Dr. Amit Kumar , was interviewed on NewsNation's "Elizabeth Vargas Reports" to discuss Anixa's breast cancer vaccine. The segment highlighted the potential of Anixa's vaccine to revolutionize the treatment and prevention of breast cancer.
Jun 02, 2025
7:00 AM EDT
The completion of enrollment in the Phase 1 clinical trial of its breast cancer vaccine. This novel vaccine, invented at Cleveland Clinic, is also being developed in partnership with Cleveland Clinic and the Phase 1 trial is fully funded by a grant from the U.S. Department of Defense (DoD).
May 19, 2025
8:00 AM EDT
A letter to shareholders from Chairman and CEO Dr. Amit Kumar , detailing significant progress across its programs and outlining key milestones for the remainder of the year.
May 12, 2025
8:00 AM EDT
Dr. Pamela D. Garzone , Chief Development Officer of Anixa, will present a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 – June 3, 2025 , in Chicago, Illinois . Lead author on the poster is Dr.
Apr 30, 2025
8:00 AM EDT
Its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference, to be held on May 20, 2025 , at Nasdaq World Headquarters in New York City .
Apr 14, 2025
8:00 AM EDT
It has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application covering its chimeric antigen receptor-T cell (CAR-T) technology.
Apr 09, 2025
8:00 AM EDT
The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new patent related to the Company's innovative breast cancer vaccine technology. The patent along with others related to this technology, has been exclusively licensed to Anixa Biosciences, by Cleveland Clinic.
